Blue Cross Blue Shield - Iowa PTNS Policy Update

Coverage and Medical Necessity Criteria

Initial 12-week percutaneous PTNS

Covered when ALL of the following are met:

Initial percutaneous PTNS coverage criteria: 1) Non-neurogenic urinary dysfunction including overactive bladder; 2) Failed behavioral therapy after an appropriate duration of 8 to 12 weeks without meeting treatment goals; 3) Failed pharmacologic therapy following 4 to 8 weeks of treatment without meeting treatment goals; 4) Planned initial course consists of 12 weekly treatments (typically 12 weekly 30-minute office-based sessions).12-week initial course

From Medically Necessary and Treatment descriptions

Maintenance percutaneous PTNS

Covered when ALL of the following are met:

Maintenance percutaneous PTNS coverage criteria: 1) Documented response to an initial 12-week course of PTNS that resulted in improved urinary dysfunction meeting treatment goals; 2) Maintenance therapy delivered on an individualized schedule typically every 4-6 weeks or monthly; 3) Annual physician evaluation may be performed to ensure continued efficacy but is not required for continued approval when criteria are met.maintenance interval typical every 4-6 weeks

From Medically Necessary and Policy Guidelines

Investigational / Not Medically Necessary

Not covered (considered investigational) for the following:

Investigational indications: 1) Percutaneous PTNS that does not meet the specified initial or maintenance criteria; 2) PTNS for neurogenic bladder dysfunction; 3) Implantable PTNS delivered by a peripheral neurostimulator system (e.g., eCoin) for all indications.

Policy Investigational section

Initial PTNS therapy — coverage criteria

Covered when ALL of the following are met:

Initial PTNS coverage criteria: 1) Individual has non-neurogenic urinary dysfunction including overactive bladder or urgency urinary incontinence; 2) Symptoms have persisted (trial eligibility commonly ≥3 months) or have failed conservative care; 3) Patient has failed behavioral and pharmacologic therapy (or documented intolerance) per policy durations; 4) Baseline symptom assessment documented (eg, OAB questionnaire, 3-day voiding diary); 5) Treatment planned as standard 12 weekly 30-minute sessions with documented response assessment at ~13 weeks (eg, GRA responder assessment).see node text

Derived from trial eligibility and protocol descriptions (SUmiT, OrBIT)

Implantable/subcutaneous tibial nerve stimulation — coverage criteria

Covered when ALL of the following are met:

Implantable device coverage criteria: 1) Diagnosis of urgency urinary incontinence; 2) Patient is intolerant of or had inadequate response to more conservative treatments OR had a successful trial of percutaneous PTNS; 3) Device is FDA-approved/cleared for the indication (for example, eCoin PMA approval noted in regulatory section); 4) Documentation of prior therapies and, when applicable, documented response to a trial of percutaneous PTNS before implantation.see node text

Reflects FDA indications and device labeling; policy notes limited comparative evidence

Maintenance PTNS — coverage criteria

Covered when ALL of the following are met:

Maintenance PTNS: 1) Patient was a responder to an initial 12-week PTNS course (responder often defined as moderately or markedly improved on 7-level GRA at week 13); 2) Maintenance schedule individualized after initial course with documentation of symptom recurrence prompting treatment (STEP protocol/extension studies); 3) Continued benefit documented during follow-up (eg, GRA improvement, voiding diary measures).responder definition per SUmiT/STEP

Based on SUmiT trial and STEP extension outcomes

Initial Course of Percutaneous PTNS

Covered when ALL of the following are met

Initial PTNS: 1) Non-neurogenic urinary dysfunction including OAB with urgency urinary incontinence; 2) Failure of behavioral and pharmacologic therapy per policy durations; 3) Candidate for and willing to undergo an initial percutaneous PTNS course (eg, 12 weekly 30-minute office-based sessions).12-week initial course

Based on randomized trial evidence including SUmiT and OrBIT

Maintenance / Implantable PTNS

Covered when ALL of the following are met

Maintenance or Implantable PTNS: 1) Patient responded to an initial percutaneous PTNS course; 2) Maintenance PTNS is clinically indicated with documented recurrence or worsening of symptoms managed by periodic PTNS; 3) For implantable device consideration, documentation of expected maintenance regimen and prior percutaneous response is provided; 4) Patient prefers or is appropriate to avoid more invasive interventions (eg, botulinum toxin, sacral neuromodulation).typical maintenance every 4-6 weeks

Observational extension studies support durability in responders; optimal interval unclear

Coverage evidence statements

Summary of evidence and applicability

Implantable PTNS for non-neurogenic OAB: Evidence consists primarily of single-arm, open-label studies (eg, eCoin) with a reported ~68% responder rate at 48 weeks but no randomized controlled trials; certainty limited by lack of comparator and other study limitations (eg, pandemic effects); ongoing postapproval study may clarify benefit and safety (eg, reimplantation/battery life).responders ~68% reported in pivotal single-arm study

Use when documenting refractory OAB after prior therapies; lack of RCTs limits certainty

Percutaneous/Transcutaneous PTNS for neurogenic bladder: Few RCTs exist (mostly transcutaneous stimulation), heterogeneous populations and comparators, and study findings have not demonstrated consistent significant benefit; evidence is insufficient (eg, Hayes D2 rating) to support use for neurogenic lower urinary tract dysfunction.none

Considered investigational/unproven for neurogenic LUT dysfunction based on current evidence

Maintenance PTNS (initial response required)

Covered when ALL of the following are met

Maintenance PTNS eligibility: Patient has non-neurogenic urinary dysfunction (including overactive bladder); patient has failed behavioral and pharmacologic therapy per policy; patient responded to an initial course of PTNS; maintenance PTNS is recommended by the treating clinician in a shared decision-making context.response to initial PTNS course

Based on clinical input and guideline statements

Maintenance PTNS (clinical input)

Clinical input summarized — describes when PTNS (including maintenance) is considered meaningful:

Maintenance PTNS considered clinically meaningful: For individuals with non-neurogenic urinary dysfunction (including overactive bladder) who have failed behavioral and pharmacologic therapy AND who respond to an initial course of percutaneous tibial nerve stimulation, maintenance PTNS may provide clinically meaningful improvement in net health outcome according to clinician respondents; common practice is induction once weekly for 12 weeks then maintenance every 4-6 weeks or monthly.response to initial PTNS course

Clinical respondents recommended induction weekly x12 then maintenance every 4-6 weeks; annual physician follow-up often performed

Implantable posterior tibial nerve stimulation devices (for example, the eCoin peripheral neurostimulator) are designated in this policy as investigational for all indications and are therefore excluded from coverage. This reflects the policy determination that current evidence is insufficient to establish an improvement in net health outcomes for implantable PTNS systems across indications.

Patients with neurogenic bladder dysfunction are not the primary population addressed by the coverage criteria for PTNS. For treatment decision-making, botulinum toxin and sacral nerve stimulation are cited comparators; botulinum toxin carries an increased risk of urinary retention and is not recommended for patients with a history of urinary retention or recurrent urinary tract infections.

When selecting therapies and comparators, clinicians should consider contraindications to alternative treatments. For example, botulinum toxin is contraindicated or not recommended in patients with prior urinary retention or recurrent UTI. The policy notes that some nonmedical factors (for example, geographic distance limiting weekly visits) may effectively exclude patients from percutaneous PTNS in practice.

Use of PTNS for neurogenic lower urinary tract dysfunction is supported only by a limited and very low–quality body of evidence. A Hayes Health Technology Assessment gave PTNS for neurogenic LUT dysfunction a D2 rating (insufficient evidence), and published randomized trials—many using transcutaneous stimulation—have not consistently shown benefit; therefore evidence is currently inadequate to establish improved net health outcomes in this population.

The American College of Obstetricians and Gynecologists practice bulletin (2015) did not address PTNS. The American Urological Association/SUFU guidance (2019, 2024) mentions PTNS as a minimally invasive or third-line option in selected patients, but carries a grade C rating indicating uncertain balance of benefits and risks; AUA/SUFU guidance allows PTNS in shared decision-making contexts.

Clinical respondents and the policy note nonmedical factors that affect access: patients who live far from treatment centers may decline weekly induction visits. Respondents also discussed variable practice patterns and rare potential exclusions (for example, concerns about peripheral neuropathy), but no uniform medical exclusions beyond the investigational indications are specified in the policy.

Percutaneous PTNS for neurogenic bladder is considered investigational because randomized trials have been few, often used transcutaneous rather than percutaneous modalities, and have yielded inconsistent results. The implantable tibial neurostimulator evidence base is primarily single-arm studies without randomized comparators; for implantable systems the lack of controlled data prevents establishing net clinical benefit, providing the rationale for investigational status.

Long-term maintenance PTNS without documentation of an initial positive response raises concerns about efficacy. Randomized and sham-controlled trials support benefit for the standard 12-week induction regimen, but concurrent controlled evidence is limited for long-term maintenance, so coverage for extended maintenance generally requires documentation of an initial response to the induction course.

Percutaneous PTNS is positioned as a treatment option after failure of behavioral and pharmacologic therapies. Use of PTNS without documented prior conservative therapy failure, or without documented response to an initial percutaneous PTNS course before placement of an implantable device, is not consistent with the policy’s stepwise sequencing and may be considered not medically necessary.

Randomized controlled trials and systematic reviews show benefit of percutaneous PTNS when applied in the standard 12‑week regimen for non‑neurogenic OAB in selected trials (for example, SUmiT and OrBIT). However, trials are heterogeneous, many small, and some sham‑controlled or device‑type comparisons (including transcutaneous stimulation) have not consistently shown significant effects in neurogenic populations. Overall quality of evidence for long‑term maintenance and for neurogenic bladder remains limited.

Guidelines and systematic reviews frame PTNS as a minimally invasive option with mixed-quality evidence: randomized, placebo-controlled trials support short‑term efficacy of the standard 12‑week PTNS induction, but guideline recommendations (AUA/SUFU) carry grade C or expert‑opinion statements and emphasize shared decision‑making given uncertain long‑term benefit and variable comparative effectiveness versus other therapies.

Clinical input from practicing physicians supports maintenance PTNS for patients with non‑neurogenic OAB who responded to an initial induction course, describing the regimen as weekly for 12 weeks then maintenance every 4–6 weeks or monthly. Respondents indicated that maintenance PTNS can be clinically meaningful in this context and is consistent with generally accepted practice when documented benefit exists.

Procedure, Device and Category Codes

Category III / Emerging Technology CodesmixedExperimental

Category III codes

Temporary (T) codes for emerging technologies; all Category III codes will be considered investigational unless explicitly addressed as covered in policy.

Regulatory device identifiers mentionedmixed

P200036	FDA PMA number for eCoin Peripheral Neurostimulator System (Valencia Technologies)
QPT	FDA Product Code for eCoin Peripheral Neurostimulator System
K052025	510(k) for Urgent PC Neuromodulation System
K061333	510(k) for Urgent PC Neuromodulation System
K071822	510(k) for Urgent PC Neuromodulation System
K101847	510(k) for Urgent PC Neuromodulation System
K132561	510(k) for NURO Neuromodulation System

Altaviva device identifiermixed

P240011

510(k) listed for Altaviva Implantable Tibial Neuromodulation System (Medtronic)

Device described (no billing codes listed in excerpt)mixed

No codes listed

Procedure Codes (listed)CPT | HCPCS | mixed

0816T	Implantation of integrated neurostimulation system for bladder dysfunction including electrode(s) (e.g., array or leadless), and pulse generator or receiver.
64566	Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming.
64999	Unlisted procedure, nervous system (when specified for eCoin).
0587T	Percutaneous implantation or replacement of integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve.
0588T	Revision or removal of percutaneously placed integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve.
0589T	Electronic analysis with simple programming of implanted integrated neurostimulation system for bladder dysfunction, posterior tibial nerve, 1-3 parameters.
0590T	Electronic analysis with complex programming of implanted integrated neurostimulation system for bladder dysfunction, posterior tibial nerve, 4 or more parameters.

Procedure CPT/Category IIICPT

0816T	Implantation of integrated neurostimulation system for bladder dysfunction including electrode(s) and pulse generator or receiver.
64566	Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming.
64999	Unlisted procedure, nervous system (when specified for eCoin).
0587T	Percutaneous implantation or replacement of integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve.
0588T	Revision or removal of percutaneously placed integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve.
0589T	Electronic analysis with simple programming of implanted integrated neurostimulation system for bladder dysfunction, posterior tibial nerve, 1-3 parameters.
0590T	Electronic analysis with complex programming of implanted integrated neurostimulation system for bladder dysfunction, posterior tibial nerve, 4 or more parameters.

Additional procedure and supply codesmixed

0816T	Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrodes(s) and pulse generator or receiver, including analysis, programming, and imaging guidance, posterior tibial nerve; subcutaneous.
0817T	Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrodes(s) and pulse generator or receiver, including analysis, programming, and imaging guidance, posterior tibial nerve; subfascial.
0818T	Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, posterior tibial nerve; subcutaneous.
0819T	Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, posterior tibial nerve; subfascial.
L8679	Implantable neurostimulator, pulse generator; any type.
C1787	Patient Programmer, Neurostimulator.
C1820	Generator, neurostimulator (implantable), with rechargeable battery and charging system.

inv-31: Initial PTNS course duration

DurationInitial course: 12 weekly office-based treatments (standard induction regimen)

Session lengthApproximately 30 minutes per session as used in pivotal trials

Stimulation parameters (typical)Low-voltage electrical stimulation (approx. 10 mA, 1–10 Hz) delivered via needle above the medial malleolus

inv-32: Maintenance PTNS interval

Typical maintenance intervalEvery 4–6 weeks (monthly commonly used)

Prior Authorization, Documentation and Operational Requirements

Note

Prior Approval

Not applicable. Prior approval is not required for PTNS under this policy; however, medical necessity criteria must be met for coverage of initial and maintenance percutaneous PTNS.

Prior Authorization

Prior Authorization for Initial and Maintenance Therapy

Prior authorization may be required by the plan for initial and maintenance percutaneous PTNS in some cases — confirm with payer. Coverage is limited to individuals meeting medical necessity criteria: failure of behavioral therapy (8–12 weeks) and pharmacologic therapy (4–8 weeks) for the initial 12-week course, and documented response to the initial 12-week course for maintenance monthly PTNS.

Initial course: failed behavioral therapy (8–12 weeks) and failed pharmacologic therapy (4–8 weeks).
Maintenance therapy: documented improvement after a 12-week initial PTNS course.

Background and Evidence Summary

Background: Posterior tibial nerve stimulation (PTNS) is an electrical neuromodulation technique used primarily to treat voiding dysfunction such as overactive bladder. Percutaneous PTNS is delivered by inserting a needle electrode above the medial malleolus to stimulate the posterior tibial nerve with low‑voltage electrical pulses, typically administered as a 12‑week induction of weekly 30‑minute sessions followed by individualized maintenance. Implantable subcutaneous tibial nerve stimulators provide automated intermittent stimulation without ongoing outpatient needle sessions.

Coverage evidence statements (duplicated in background context)

Summary of evidence and applicability

Implantable PTNS evidence summary: No randomized controlled trials identified for implantable PTNS; pivotal open-label single-arm eCoin study reported 68% responder rate at 48 weeks but certainty limited by lack of comparator and study limitations; ongoing postapproval study may clarify benefit and safety.responders ~68% at 48 weeks

Section summary for implantable tibial nerve stimulation

Definitions and Device Descriptions

inv-60: Non-Neurogenic Voiding Dysfunction definition

DefinitionNon-neurogenic voiding dysfunction: voiding dysfunction due to pelvic floor neuromuscular changes, inflammation, medication effects, obesity, or psychogenic factors; includes overactive bladder characterized by frequency, urgency, urge incontinence, and nonobstructive retention.

Examples of causesPregnancy/childbirth, pelvic surgery, medications (diuretics, anticholinergics), obesity, psychogenic factors

DistinctionExcludes bladder dysfunction caused by neurologic damage (neurogenic bladder)

inv-61: Percutaneous PTNS definition

Definition (procedure)Percutaneous PTNS: insertion of a needle above the medial malleolus into the posterior tibial nerve with low-voltage electrical stimulation (approx. 10 mA, 1–10 Hz)

Delivery

Policy Changes and History

2025-09Annual Review / RenewalLatest

Policy renewed following annual review; documented in policy history as 'September 2025: Annual Review; Action = Policy Renewal'.

2024-09Annual Review / Revision

Policy revised during the September 2024 annual review; action recorded as 'Policy Revised'.

2023-08Annual Review / Revision

OpenPayer

Percutaneous and Implantable Posterior Tibial Nerve Stimulation

Coverage and Medical Necessity Criteria

Procedure, Device and Category Codes

Prior Authorization, Documentation and Operational Requirements

Background and Evidence Summary

Definitions and Device Descriptions

Policy Changes and History